Close Menu

NEW YORK – Drug developer Merus said on Monday that it will work with molecular testing firm Caris Life Sciences to test cancer patients for NRG1 fusions and potentially enroll patients who have the genetic alterations into its Phase I/II eNRGy trial for the bispecific antibody zenocutuzumab.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.